0001134657-26-000010.txt : 20260512 0001134657-26-000010.hdr.sgml : 20260512 20260512194742 ACCESSION NUMBER: 0001134657-26-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260508 FILED AS OF DATE: 20260512 DATE AS OF CHANGE: 20260512 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EVNIN LUKE CENTRAL INDEX KEY: 0001134657 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40366 FILM NUMBER: 26970427 MAIL ADDRESS: STREET 1: 399 BOYLSTON STREET STREET 2: SUITE 1100 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Werewolf Therapeutics, Inc. CENTRAL INDEX KEY: 0001785530 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 823523180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TALCOTT AVENUE STREET 2: 2ND FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-952-0555 MAIL ADDRESS: STREET 1: 200 TALCOTT AVENUE STREET 2: 2ND FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4-05122026_110537.xml X0609 4 2026-05-08 0001785530 Werewolf Therapeutics, Inc. HOWL 0001134657 EVNIN LUKE false C/O MPM BIOIMPACT LLC 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 true false false false 1 Common Stock 2026-05-08 4 S 0 305741 0.70 D 1273008 I See Footnotes Common Stock 2026-05-11 4 S 0 33948 0.67 D 1239060 I See Footnotes Common Stock 2026-05-12 4 S 0 67885 0.64 D 1171175 I See Footnotes Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026. The shares were sold as follows: 32,757 by MPM Asset Management LLC ("AM LLC"), 206,820 by MPM BioVentures 2014, L.P. ("BV 2014"), 13,795 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 7,119 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 45,250 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6183 to $0.7668 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares are held as follows: 136,390 by AM LLC, 861,140 by BV 2014, 57,435 by BV 2014(B), 29,638 by AM BV2014 and 188,405 by MPM OIF. The shares were sold as follows: 3,637 by AM LLC, 22,965 by BV 2014, 1,532 by BV 2014(B), 790 by AM BV2014 and 5,024 by MPM OIF. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.7002 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 132,753 by AM LLC, 838,175 by BV 2014, 55,903 by BV 2014(B), 28,848 by AM BV2014 and 183,381 by MPM OIF. The shares were sold as follows: 7,273 by AM LLC, 45,921 by BV 2014, 3,063 by BV 2014(B), 1,581 by AM BV2014 and 10,047 by MPM OIF. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6286 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 125,480 by AM LLC, 792,254 by BV 2014, 52,840 by BV 2014(B), 27,267 by AM BV2014 and 173,334 by MPM OIF. /s/ Luke Evnin 2026-05-12